Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Dynamic susceptibility contrast MRI measures of relative cerebral blood volume continue to show promise as an early response marker in the setting of bevacizumab treatment. Neuro Oncol 2015 Nov;17(11):1538-9

Date

09/13/2015

Pubmed ID

26361983

Pubmed Central ID

PMC4648309

DOI

10.1093/neuonc/nov163

Scopus ID

2-s2.0-84946558454   4 Citations

Author List

Boxerman JL, Schmainda KM, Zhang Z, Barboriak DP

Author

Kathleen M. Schmainda PhD Professor in the Biophysics department at Medical College of Wisconsin




MESH terms used to index this publication - Major topics in bold

Angiogenesis Inhibitors
Bevacizumab
Brain Neoplasms
Cerebral Cortex
Female
Glioblastoma
Humans
Magnetic Resonance Imaging
Male